中国东部三市耐多药结核病患者经济负担研究

李志鹏, 盛宇超, 张杨, 周慧, 张海清, 孟旭, 赵琦

复旦学报(医学版) ›› 2021, Vol. 48 ›› Issue (04) : 481-487.

PDF(784 KB)
欢迎访问《复旦学报(医学版)》官方网站,今天是 2025年6月30日 星期一 分享到:
PDF(784 KB)
复旦学报(医学版) ›› 2021, Vol. 48 ›› Issue (04) : 481-487. DOI: 10.3969/j.issn.1672-8467.2021.04.009
论著

中国东部三市耐多药结核病患者经济负担研究

  • 李志鹏1, 盛宇超1, 张杨2, 周慧2, 张海清3, 孟旭4, 赵琦1
作者信息 +

Study on the economic burden of multi-drug resistant tuberculosis patients in three cities in eastern China

  • LI Zhi-peng1, SHENG Yu-chao1, ZHANG Yang2, ZHOU Hui2, ZHANG Hai-qing3, MENG Xu4, ZHAO Qi1
Author information +
文章历史 +

摘要

目的 了解中国东部三市耐多药结核病(multi-drug resistant tuberculosis,MDR-TB)患者的经济负担情况,寻找减轻患者经济负担的方法。方法 采用自行设计的调查问卷对正在治疗的江苏省徐州市、宿迁市和江西省赣州市定点医院登记治疗的MDR-TB患者进行面对面调查,对已经结束治疗的患者进行电话调查,收集患者基本情况、经济负担等信息。采用χ2检验、线性回归等方法分析MDR-TB患者的经济负担情况。结果 三市共登记治疗MDR-TB患者233例,其中接受全球基金项目医疗费减免患者82人,最终151例患者纳入分析,平均年龄(43.36±16.18)岁,男性患者124例(82.1%)。MDR-TB患者直接经济负担平均为28 987元,中位数为23 740(14 100~37 580)元。多因素线性回归结果显示徐州患者直接经济负担显著高于宿迁(P=0.001)和赣州(P<0.001)。治疗前MDR-TB患者家庭年收入中位数为40 000(2 0000~60 000)元,患者个人收入中位数为15 000(0~36 000)元。所有患者中产生灾难性卫生支出的家庭比例为48.3%,徐州市患者产生灾难性卫生支出的家庭比例显著高于另两市(P=0.003)。结论 中国东部三市MDR-TB患者经济负担较重,因医保报销政策和用药方案的不同而差异较大。政府应该加强医疗保险的报销范围或报销力度,增加MDR-TB患者的费用补贴,减轻患者的经济负担。

Abstract

Objective To understand the economic burden of multi-drug resistant tuberculosis (MDR-TB) patients in three cities in eastern China,and to find ways to reduce the financial burden on the patients. Methods The subjects of the study were MDR-TB patients registered and treated in designated hospitals in Xuzhou,Suqian of Jiangsu Province and Ganzhou of Jiangxi Province.Face-to-face investigation was conducted on the patients undergoing treatment,and telephone survey was conducted on the patients who have completed treatment by a self-designed questionnaire to collect demographic sociological information and economic burden of MDR-TB patients.χ2 test and linear regression were used to analyze the economic burden of MDR-TB patients. Results A total of 233 patients with MDR-TB were registered in the 3 cities,of which 82 patients received reduction of medical expenses from global fund projects.Therefore,151 patients with an average age of (43.36±16.18) years were successfully investigated finally.There were 124 male patients (82.1%).The total direct financial burden of MDR-TB patients was 28 987 yuan on average, with a median of 23 740 (14 100-37 580) yuan.The results of multivariate linear regression showed that the direct economic burden of the patients in Xuzhou was significantly higher than that in Suqian (P=0.001) and Ganzhou (P<0.001).The annual median family income of MDR-TB patients before treatment was 40 000 (20 000-60 000) yuan,and the median family income before treatment was 20 000 (0-36 000) yuan. The percentage of families with catastrophic health expenditure was 48.3%.The proportion of patients with catastrophic health expenditure in Xuzhou was significantly higher than that in the other two cities (P=0.003). Conclusion The economic burden of MDR-TB patients in the 3 cities in eastern China was heavy and varied greatly with different medical insurance policies and therapeutic regimens.The government should strengthen the coverage or reimbursement of medical insurance,and increase the subsidy of MDR-TB patients to reduce the economic burden on patients.

引用本文

导出引用
李志鹏, 盛宇超, 张杨, 周慧, 张海清, 孟旭, 赵琦. 中国东部三市耐多药结核病患者经济负担研究[J]. 复旦学报(医学版), 2021, 48(04): 481-487 https://doi.org/10.3969/j.issn.1672-8467.2021.04.009
LI Zhi-peng, SHENG Yu-chao, ZHANG Yang, ZHOU Hui, ZHANG Hai-qing, MENG Xu, ZHAO Qi. Study on the economic burden of multi-drug resistant tuberculosis patients in three cities in eastern China[J]. Fudan University Journal of Medical Sciences, 2021, 48(04): 481-487 https://doi.org/10.3969/j.issn.1672-8467.2021.04.009
中图分类号: R19    R52   

参考文献

[1] WORLD HEALTH ORGANIZATION.Global Tuberculosis Report 2019[EB/OL].(2019-10-17)[2020-11-25].https://www.who.int/teams/global-tuberculosis-programme/tb-reports.
[2] BHERING M,DUARTE R,KRITSKI A.Predictive factors for unfavourable treatment in MDR-TB and XDR-TB patients in Rio de Janeiro State,Brazil,2000-2016[J].PLoS One,2019,14(11):e0218299.
[3] SEAWORTH BJ,GRIFFITH DE.Therapy of multidrug-resistant and extensively drug-resistant tuberculosis[J].Microbiol Spectr,2017,5(2):1-24.
[4] KANG YA,CHOI YJ,CHO YJ,et al.Cost of treatment for multidrug-resistant tuberculosis in South Korea[J].Respirology,2006,11(6):793-798.
[5] MANJELIEVSKAIA J,ERCK D,PIRACHA S,et al.Drug-resistant TB:deadly,costly and in need of a vaccine[J].Trans R Soc Trop Med Hyg,2016,110(3):186-191.
[6] UKWAJA KN,ALOBU I,ABIMBOLA S,et al.Household catastrophic payments for tuberculosis care in Nigeria:incidence,determinants,and policy implications for universal health coverage[J].Infect Dis Poverty,2013,2(1):21.
[7] TANIMURA T,JARAMILLO E,WEIL D,et al.Financial burden for tuberculosis patients in low- and middle-income countries:a systematic review[J].Eur Respir J,2014,43(6):1763-1775.
[8] EVANS DB,ETIENNE C.Health systems financing and the path to universal coverage[J].Bull World Health Organ,2010,88(6):402-403.
[9] BARR RG,DIEZ-ROUX AV,KNIRSCH CA,et al.Neighborhood poverty and the resurgence of tuberculosis in New York City,1984-1992[J].Am J Public Health,2001,91(9):1487-1493.
[10] FENG M,XU Y,ZHANG X,et al.Risk factors of multidrug-resistant tuberculosis in China:a meta-analysis[J].Public Health Nurs,2019,36(3):257-269..
[11] 王国杰,刘靖恒,Sleigh Adrian,等.河南省农村家庭经济条件与肺结核病之间的关系研究[J].中国卫生经济,2006,25(3):52-56.
[12] 胡逸欢,陈勇,吴哲渊,等.上海市耐多药肺结核患者治疗减免政策实施现况分析[J].中国卫生资源,2017,20(5):422-425.
[13] 孙强,闫赟,边学峰,等.耐多药肺结核患者医疗费用及经济负担分析[J].中国卫生经济,2011,30(1):33-35.
[14] COX H,RAMMA L,WILKINSON L,et al.Cost per patient of treatment for rifampicin-resistant tuberculosis in a community-based programme in Khayelitsha,South Africa[J].Trop Med Int Health,2015,20(10):1337-1345.
[15] 徐彩红,马伟,张灿有,等.耐多药肺结核诊疗费用在不同的医疗保障制度中的报销情况分析[J].中国预防医学杂志,2014,15(7):633-636.
[16] 申丽君,王艺曈,李雪,等.基于疗程费用测算耐药结核病患者药物负担[J].中国防痨杂志,2019,41(9):962-967.

基金

上海市第四轮公共卫生三年行动计划(15GWZK0101)
PDF(784 KB)

353

Accesses

0

Citation

Detail

段落导航
相关文章

/